4-氯-3-硝基水杨基苯胺 | 6490-99-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-3-硝基水杨基苯胺
• 英文名称: 4'-chloro-2-hydroxy-3-nitrobenzanilide
• 英文别名: N-(4-chlorophenyl)-3-nitro-2-oxoniobenzenecarboximidate
• CAS: 6490-99-9
• 化学式: C₁₃H₉ClN₂O₄
• 分子量: 292.678
• InChiKey: UOHLBUBEMXVTMQ-UHFFFAOYSA-N

物化性质

• 溶解度：
  2.85e-05 M

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090

反应信息

• 作为产物：
  描述：

  3-硝基水杨酸 在 氯化亚砜 、 苯 作用下， 生成 4-氯-3-硝基水杨基苯胺
  参考文献：
  名称：

  Taborsky et al., Journal of the American Pharmaceutical Association (1912), 1959, vol. 48, p. 503,505

  摘要：

  DOI：

文献信息

• Halogenated salicylanilides for treating clostridium infections
  申请人：UNION therapeutics A/S

  公开号：US10463680B2

  公开（公告）日：2019-11-05

  The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhea and C. difficile associated colitis.

  本发明涉及卤代水杨酰苯胺或其药学上可接受的盐或酯，用于治疗梭状芽孢杆菌引起的受试者感染，特别是艰难梭菌感染。卤代水杨酰苯胺有望用于治疗艰难梭菌相关疾病，包括艰难梭菌相关腹泻和艰难梭菌相关结肠炎。
• Antibacterial use of halogenated salicylanilides
  申请人：UNION therapeutics A/S

  公开号：US10758553B2

  公开（公告）日：2020-09-01

  The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.

  本发明涉及一种卤代水杨酰苯胺，选自closingantel、rafoxanide、oxyclozanide和niclosamide及其衍生物，包括盐类、水合物、酯类等，用于局部治疗或预防革兰氏阳性菌如葡萄球菌，特别是金黄色葡萄球菌和链球菌，特别是化脓性链球菌引起的感染。与常用的局部抗生素相比，使用卤代水杨酰苯胺处理的革兰氏阳性细菌出现抗药性突变体的频率非常低。
• Halogenated salicylanilides for treating Clostridium infections
  申请人：UNION therapeutics A/S

  公开号：US10857164B2

  公开（公告）日：2020-12-08

  The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.

  本发明涉及卤代水杨酰苯胺或其药学上可接受的盐或酯，用于治疗梭状芽孢杆菌引起的受试者感染，特别是艰难梭菌感染。卤代水杨酰苯胺有望用于治疗艰难梭菌相关疾病，包括艰难梭菌相关腹泻和艰难梭菌相关结肠炎。
• Compositions and methods for protecting a host from enteric toxigenic pathogens
  申请人：The Hospital For Sick Children

  公开号：US11166926B2

  公开（公告）日：2021-11-09

  A method of protecting a host from an enteric toxigenic pathogen comprises administering a salicylanilide to the host. A method of reducing virulence of an enteric toxigenic pathogen comprises administering a salicylanilide to a host infected with or at risk of infection with pathogen. A method of reducing recurrence of an infection caused by an enteric toxigenic pathogen, comprises administering a salicylanilide to a host previously infected with the pathogen.

  一种保护宿主免受肠毒性病原体感染的方法包括向宿主施用水杨酰苯胺。一种降低肠道毒性病原体毒力的方法，包括向感染或有可能感染病原体的宿主施用水杨酰苯胺。一种减少由肠道致毒病原体引起的感染复发的方法，包括向先前感染病原体的宿主施用水杨酰苯胺。
• US11529361B2
  申请人：UNION therapeutics A/S

  公开号：US11529361B2

  公开（公告）日：2022-12-20

  The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.

  本发明涉及卤代水杨酰苯胺或其药学上可接受的盐或酯，用于治疗梭状芽孢杆菌引起的受试者感染，特别是艰难梭菌感染。 卤代水杨酰苯胺有望用于治疗艰难梭菌相关疾病，包括艰难梭菌相关腹泻和艰难梭菌相关结肠炎。